Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Insider Sells 1,290 Shares of Stock

Key Points

• Insider sale: Douglas Kerr sold 1,290 Dyne Therapeutics shares at an average price of $18.88, totaling $24,355.20. The transaction covered tax withholding obligations and reduced his holdings by 0.79%.
• Stock and financial performance: DYN fell to $20.31 during Tuesday trading, while the company reported quarterly EPS of $(1.08), missing the $(0.75) consensus estimate. Institutional investors own approximately 96.68% of the stock.
• Upcoming catalysts and risks: Dyne plans to present updated ACHIEVE trial data for its DM1 therapy on September 30, with registrational-cohort topline results targeted for Q1 2027. Analysts maintain a “Moderate Buy” consensus with a $34.17 price target, though sentiment has been pressured by a rival DM1 drug’s failed Phase 3 trial.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) insider Douglas Kerr sold 1,290 shares of the business's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total transaction of $24,355.20. Following the transaction, the insider directly owned 162,564 shares of the company's stock, valued at approximately $3,069,208.32. This trade represents a 0.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Friday, September 4th, Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock. The stock was sold at an average price of $24.35, for a total transaction of $91,190.75.

Dyne Therapeutics Stock Performance

NASDAQ:DYN traded down $3.97 during mid-day trading on Tuesday, hitting $20.31. The stock had a trading volume of 17,067,421 shares, compared to its average volume of 2,151,348. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The company has a 50 day simple moving average of $24.86 and a 200-day simple moving average of $20.45. The stock has a market capitalization of $3.79 billion, a price-to-earnings ratio of -6.10 and a beta of 1.08. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Nykredit A S acquired a new stake in shares of Dyne Therapeutics during the second quarter valued at approximately $113,000. California State Teachers Retirement System grew its position in Dyne Therapeutics by 2,049.2% during the 2nd quarter. California State Teachers Retirement System now owns 3,001,615 shares of the company's stock worth $66,666,000 after purchasing an additional 2,861,952 shares in the last quarter. Moore Capital Management LP raised its stake in Dyne Therapeutics by 288.2% during the 2nd quarter. Moore Capital Management LP now owns 305,794 shares of the company's stock valued at $6,792,000 after purchasing an additional 227,029 shares during the period. Two Sigma Securities LLC purchased a new stake in shares of Dyne Therapeutics in the second quarter valued at $222,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Dyne Therapeutics in the second quarter worth $5,448,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month ACHIEVE data at the World Muscle Society and AANEM meetings on September 30. The presentations will compare a pooled treated group with a matched natural-history cohort and include updated safety information. Topline data from the fully enrolled registrational expansion cohort remain targeted for Q1 2027. Dyne ACHIEVE data announcement
• Positive Sentiment: Z-basivarsen has received FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, while Dyne is advancing the program into the Phase 3 HARMONIA trial. These regulatory designations and upcoming data could provide future catalysts if clinical benefit is confirmed.
• Neutral Sentiment: Options activity was unusually high, with traders purchasing approximately 20,532 call contracts—more than 40 times the average daily call volume. This may reflect speculative positioning ahead of clinical presentations, but it does not establish a fundamental change in the company’s outlook.
• Neutral Sentiment: Several insiders, including CEO John Cox, Chief Medical Officer Douglas Kerr and Chief Commercial Officer Johanna Friedl-Naderer, reported small stock sales. The filings state that the transactions were made to cover tax withholding obligations from vested equity awards, reducing their negative significance.
• Negative Sentiment: Investor sentiment was pressured after a competing DM1 drug reportedly failed in a Phase 3 trial. The result may have increased concern about the difficulty of demonstrating meaningful clinical benefit in DM1 and raised the risk profile ahead of Dyne’s own data release. DM1 rival trial news
• Negative Sentiment: No company-specific negative clinical result was confirmed in the reports. However, the absence of new efficacy data today, combined with uncertainty surrounding the upcoming one-year results and the delay until Q1 2027 for registrational-cohort topline data, left DYN vulnerable to profit-taking and risk reduction. Dyne share decline report

Wall Street Analyst Weigh In

Several research firms have commented on DYN. Raymond James Financial reissued a "strong-buy" rating and set a $37.00 target price on shares of Dyne Therapeutics in a research note on Tuesday. Sanford C. Bernstein boosted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a research note on Wednesday, May 13th. Evercore set a $33.00 target price on Dyne Therapeutics in a research note on Friday, May 15th. Royal Bank Of Canada boosted their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Thursday, July 30th. Finally, Cantor Fitzgerald initiated coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an "overweight" rating on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.